carfilzomib,dexamethasone,isatuximab
sanofi,amgen
congress #ims2022 | roman hajek presents long-term depth of response data from the ikema trial of isa-kd vs kd, for the treatment of relapsed #mm. the results show a clinically meaningful improvement in depth of response for isa-kd. #medicalcongress #mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma